Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? Merck Animal Health is doubling down on biodevices and automation in poultry by buying TARGAN, turning from a strategic investor into full owner of high-speed sexing and precision vaccination tech Source: Businesswire...
Quick Takeaways: Why It Matters? BiomEdit’s new patents effectively lock up its engineered Lactobacillus reuteri pvAb platform, giving it composition‑of‑matter and methods‑of‑use protection around BE‑101 and future in situ biologic payloads delivered vi...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
Quick Takeaways: Why It Matters? BE-101’s move into pivotal field safety testing brings the poultry sector closer to a commercially viable, non-antibiotic solution for necrotic enteritis, addressing a major economic and welfare burden while aligning with global pressure to...
